Table 1

Demographics and clinical characteristics of patients with IMID and controls

IMIDsHC
N84182
Demographic characteristics
 Age, years53.1±17.040.8±12.0
 Females, N (%)55 (65.5)104 (57.1)
 BMI26.8±5.824.7±4.1
 Current smokers, N (%)14 (16.7)31 (17.0)
Comorbidities
 Diabetes6 (7.1)2 (1.1)
 Hypertension21 (25.0)19 (10.4)
 History of CV event1 (1.2)1 (1.0)
 History of thrombotic event00
Type of IMID
 SpA, N (%)27 (32.1)0
 RA, N (%)25 (29.8)0
 IBD, N (%)8 (9.5)0
 Psoriasis, N (%)8 (9.5)0
 Systemic*, N (%)16 (19.1)0
Immune-modulatory therapy
 No treatment, N (%)24 (28.6)0
 Glucocorticoids, N (%)10 (11.9)0
 csDMARDs monotherapy, N (%)20 (23.9)0
 MTX, N (%)16 (19.1)0
 Hydroxychloroquine, N (%)3 (3.6)0
 Sulfasalazine, N (%)1 (1.2)0
 bDMARDs/tsDMARDs, N (%)36 (42.9)0
 TNF inhibitors, N (%)11 (13.1)0
 IL-6 inhibitors, N (%)3 (3.6)0
 IL-23 inhibitors, N (%)6 (7.1)0
 IL-17 inhibitors, N (%)7 (8.3)0
 JAK inhibitors, N (%)6 (7.1)0
 Others†, N (%)3 (3.6)0
  • *Systemic lupus erythematosus, systemic sclerosis, IgG4-related disease, periodic fever syndromes, giant cell arteriitis, granulomatosis with polyangiitis and polymyalgia rheumatic.

  • †Apremilast, canakinumab and vedolizumab.

  • bDMARDs, biological disease-modifying antirheumatic drugs; BMI, body mass index; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; CV, cardiovascular; HC, healthy controls; IBD, inflammatory bowel disease; IL, interleukin; IMIDs, immune-mediated inflammatory diseases; JAK, Janus kinase; MTX, methotrexate; RA, rheumatoid arthritis; SpA, spondyloarthritis (including axial spondyloarthritis and psoriatic arthritis); TNF, tumour necrosis factor; tsDMARDs, targeted-synthetic disease-modifying antirheumatic drugs.